论文部分内容阅读
目的探讨颅内原发性中枢神经系统淋巴瘤(PCNSL)的治疗方式与疗效。方法回顾性分析2009年1月至2014年1月收治的6例颅内原发性淋巴瘤患者的临床资料。6例病例中3例经手术切除肿瘤,另3例经取活检,病理均证实为PCNSL,5例接受大剂量甲氨蝶呤为主的化疗及全脑放射治疗,统计各例治疗方案及疗效,进行分析。结果 6例患者在经过初次治疗后,完全缓解3例,部分缓解2例,稳定1例。截止2014年9月30日随访结束,6例患者中4例存活,2例死亡。3例接受手术的患者中,1例死于术后并发症,2例存活;3例未手术病例中,1例死于肿瘤进展,2例存活。5例出现复发病例平均首次复发时间为18.8个月,1例存活29个月无复发。结论大剂量甲氨蝶呤为主的化疗联合放疗是目前治疗PCNSL的主要方法,手术可改善患者的占位效应,但能否延长生存期仍有待进一步研究。
Objective To investigate the treatment and efficacy of intracranial primary central nervous system lymphoma (PCNSL). Methods The clinical data of 6 patients with intracranial primary lymphoma who were admitted from January 2009 to January 2014 were analyzed retrospectively. Three of 6 patients underwent surgical resection of the tumor. The other 3 patients underwent biopsy and pathology were confirmed as PCNSL. Five patients underwent high-dose methotrexate-based chemotherapy and whole-brain radiation therapy. The treatment and efficacy of each treatment were statistically analyzed , For analysis. Results After the initial treatment, 6 patients achieved complete remission in 3 cases, partial remission in 2 cases and stable in 1 case. As of September 30, 2014, at the end of follow-up, 4 of 6 patients survived and 2 died. Of the 3 patients who underwent surgery, 1 died of postoperative complications and 2 survived; 3 of the non-operative cases died of tumor progression and 2 survived. The average recurrence time was 18.8 months in 5 cases and 1 case survived 29 months without recurrence. Conclusions High-dose methotrexate-based chemotherapy combined with radiotherapy is the main method for the treatment of PCNSL. Surgery can improve the space-occupying effect in patients. However, whether to prolong the survival period remains to be further studied.